FO
JUNO

FT Options’s Juno Therapeutics, Inc. JUNO Stock Holding History

FT Options’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		$45K Buy
+1,000
New +$34.1K 0.07% 127

Other funds holding JUNO

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

FT Options's JUNO Position: Q3 2017 in Review

FT Options opened a new position in Juno Therapeutics, Inc. (JUNO) in Q3 2017: 1,000 shares worth $45K. The stake represents 0.07% of the portfolio and ranks #127 among its holdings.

210 funds tracked by Wall St. Rank hold JUNO as of Q3 2017.

  • FT Options held 1,000 shares of Juno Therapeutics, Inc. worth $45K as of Q3 2017.
  • Juno Therapeutics, Inc. was a new FT Options position in Q3 2017.
  • Juno Therapeutics, Inc. made up 0.07% of FT Options's portfolio in Q3 2017, its #127 holding.
  • 210 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q3 2017.

Based on FT Options's 13F filing for Q3 2017, filed 13 Nov 2017.